Pub Date : 2025-12-01Epub Date: 2025-06-11DOI: 10.1080/25787489.2025.2513684
Sheila Kansiime, Christian Holm Hansen, Henry Bern, Julie Fox, David Dunn, Eugene Ruzagira, Richard Hayes, Sheena Mc Cormack
Background: Inferring the counterfactual placebo HIV incidence using the estimated effectiveness of Emtricitabine/Tenofovir (TDF/FTC) in active-controlled pre-exposure prophylaxis (PrEP) trials has been suggested. However, it has not yet been widely applied. In this article, we evaluate adherence to TDF/FTC in the PrEPVacc trial (NCT04066881) and consider how such adherence data could be used to estimate the effectiveness of TDF/FTC and subsequently, HIV incidence in a counterfactual placebo arm in a predominantly female population.
Methods: From December 2020 to March 2023 participants were recruited into the trial which included a comparison of Emtricitabine/Tenofovir Alafenamide (TAF/FTC) to TDF/FTC as PrEP over 26 weeks of follow-up, in Uganda, Tanzania, and South Africa. PrEP adherence was assessed in various ways.
Results: Of 697 participants dispensed TDF/FTC, 87% were female, 54% were ≥ 25 years, and 59% were sex workers. In a random sample (41%) assessed at visit 6 (week 8), 76% had detectable TFV-DP levels, with 22% reaching levels consistent with ≥2 pills/week. Males, Verulam and Mbeya participants, those ≥ 25 years, not single, subsistence fisheries workers, and those who had any STI at baseline were more likely to have higher adherence. Of those assessed at visit 6, 29% were identified as white coat dosing. Estimated (crude) HIV incidence risk reduction ranged from 10% to 65%.
Conclusions: TDF/FTC adherence in the PrEPVacc trial was low, with considerable levels of white coat dosing. Inferring the counterfactual placebo HIV incidence using the estimated effectiveness of TDF/FTC is a promising approach, however, the approach requires further elaboration and evaluation.
{"title":"Evaluating adherence in an active-controlled HIV pre-exposure prophylaxis trial (PrEPVacc) to inform the estimation of HIV incidence in a counterfactual placebo arm.","authors":"Sheila Kansiime, Christian Holm Hansen, Henry Bern, Julie Fox, David Dunn, Eugene Ruzagira, Richard Hayes, Sheena Mc Cormack","doi":"10.1080/25787489.2025.2513684","DOIUrl":"10.1080/25787489.2025.2513684","url":null,"abstract":"<p><strong>Background: </strong>Inferring the counterfactual placebo HIV incidence using the estimated effectiveness of Emtricitabine/Tenofovir (TDF/FTC) in active-controlled pre-exposure prophylaxis (PrEP) trials has been suggested. However, it has not yet been widely applied. In this article, we evaluate adherence to TDF/FTC in the PrEPVacc trial (NCT04066881) and consider how such adherence data could be used to estimate the effectiveness of TDF/FTC and subsequently, HIV incidence in a counterfactual placebo arm in a predominantly female population.</p><p><strong>Methods: </strong>From December 2020 to March 2023 participants were recruited into the trial which included a comparison of Emtricitabine/Tenofovir Alafenamide (TAF/FTC) to TDF/FTC as PrEP over 26 weeks of follow-up, in Uganda, Tanzania, and South Africa. PrEP adherence was assessed in various ways.</p><p><strong>Results: </strong>Of 697 participants dispensed TDF/FTC, 87% were female, 54% were ≥ 25 years, and 59% were sex workers. In a random sample (41%) assessed at visit 6 (week 8), 76% had detectable TFV-DP levels, with 22% reaching levels consistent with ≥2 pills/week. Males, Verulam and Mbeya participants, those ≥ 25 years, not single, subsistence fisheries workers, and those who had any STI at baseline were more likely to have higher adherence. Of those assessed at visit 6, 29% were identified as white coat dosing. Estimated (crude) HIV incidence risk reduction ranged from 10% to 65%.</p><p><strong>Conclusions: </strong>TDF/FTC adherence in the PrEPVacc trial was low, with considerable levels of white coat dosing. Inferring the counterfactual placebo HIV incidence using the estimated effectiveness of TDF/FTC is a promising approach, however, the approach requires further elaboration and evaluation.</p>","PeriodicalId":13165,"journal":{"name":"HIV Research & Clinical Practice","volume":"26 1","pages":"2513684"},"PeriodicalIF":1.7,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144266054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01Epub Date: 2025-07-23DOI: 10.1080/25787489.2025.2535352
Florian Voit, Sven Breitschwerdt, Annamaria Balogh, Helen Bidner, Silvia Egert-Schwender, Christoph Boesecke, Laura Wagner, Eva Wolf, Christoph D Spinner
Objectives: This post-hoc evaluation of the DUALIS study aimed to examine cardiovascular risk and the achievement of low-density lipoprotein cholesterol (LDL-C) targets in a virologically suppressed cohort of people living with HIV in Germany.
Methods: Baseline cardiovascular risk was assessed using the European Society of Cardiology (ESC)-Systematic COronary Risk Evaluation 2 (SCORE2)/SCORE2-Older Persons (OP) and the current ESC guideline-recommended LDL-C targets among participants aged ≥40 years in the DUALIS study. Risk categorization was based on the ESC-SCORE2/SCORE2-OP results and the presence of specific comorbidities indicative of high risk and very high risk of CVD. Participants were enrolled between July 2015 and June 2017.
Results: The use of lipid-lowering therapy (LLT) was low in the DUALIS study, with 12 out of 188 participants (6%) receiving the treatment. The median ESC-SCORE2/SCORE2-OP was 5.0%. Overall, 92 participants (49%) had low-to-moderate CVD risk, 77 (41%) high risk, and 19 (10%) very high risk. Only one participant in the high-risk group and none in the very high-risk group met the guideline-recommended LDL-C targets. Even when using the less stringent LDL-C targets valid at the time of data collection (2016 ESC guideline), only 19.7% of the high-risk and none of the very high-risk participants met these targets. In addition, a strong correlation regarding the estimated CVD risk was observed between the D:A:D (R) and ESC SCORE2/SCORE2-OP scores (r = 0.95).
Conclusions: The achievement of guideline-recommended LDL-C targets was low in the high- and very high-CVD-risk groups in the DUALIS study, reflecting low utilization of LLT in clinical practice.
{"title":"Cardiovascular risk and achievement of target levels in low-density lipoprotein cholesterol in people living with HIV: insights from the DUALIS study.","authors":"Florian Voit, Sven Breitschwerdt, Annamaria Balogh, Helen Bidner, Silvia Egert-Schwender, Christoph Boesecke, Laura Wagner, Eva Wolf, Christoph D Spinner","doi":"10.1080/25787489.2025.2535352","DOIUrl":"10.1080/25787489.2025.2535352","url":null,"abstract":"<p><strong>Objectives: </strong>This <i>post-hoc</i> evaluation of the DUALIS study aimed to examine cardiovascular risk and the achievement of low-density lipoprotein cholesterol (LDL-C) targets in a virologically suppressed cohort of people living with HIV in Germany.</p><p><strong>Methods: </strong>Baseline cardiovascular risk was assessed using the European Society of Cardiology (ESC)-Systematic COronary Risk Evaluation 2 (SCORE2)/SCORE2-Older Persons (OP) and the current ESC guideline-recommended LDL-C targets among participants aged ≥40 years in the DUALIS study. Risk categorization was based on the ESC-SCORE2/SCORE2-OP results and the presence of specific comorbidities indicative of high risk and very high risk of CVD. Participants were enrolled between July 2015 and June 2017.</p><p><strong>Results: </strong>The use of lipid-lowering therapy (LLT) was low in the DUALIS study, with 12 out of 188 participants (6%) receiving the treatment. The median ESC-SCORE2/SCORE2-OP was 5.0%. Overall, 92 participants (49%) had low-to-moderate CVD risk, 77 (41%) high risk, and 19 (10%) very high risk. Only one participant in the high-risk group and none in the very high-risk group met the guideline-recommended LDL-C targets. Even when using the less stringent LDL-C targets valid at the time of data collection (2016 ESC guideline), only 19.7% of the high-risk and none of the very high-risk participants met these targets. In addition, a strong correlation regarding the estimated CVD risk was observed between the D:A:D (R) and ESC SCORE2/SCORE2-OP scores (<i>r</i> = 0.95).</p><p><strong>Conclusions: </strong>The achievement of guideline-recommended LDL-C targets was low in the high- and very high-CVD-risk groups in the DUALIS study, reflecting low utilization of LLT in clinical practice.</p>","PeriodicalId":13165,"journal":{"name":"HIV Research & Clinical Practice","volume":"26 1","pages":"2535352"},"PeriodicalIF":1.7,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144690065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Chunki Fong, Madellena Conte, Rebecca Zimba, Jennifer Carmona, Gina Gambone, Abigail Baim-Lance, McKaylee Robertson, Mary Irvine, Denis Nash
The PROMISE study assessed revisions designed to facilitate implementation of an HIV care coordination program (CCP) addressing gaps in care and treatment engagement among people living with HIV in New York City (NYC). Through latent class analysis (LCA) of a discrete choice experiment (DCE), we explored heterogeneity of provider preferences regarding CCP features. From January-March 2020, 152 NYC CCP providers completed a DCE with 3-4 levels on each of 4 program attributes: 1) Help with Adherence to Antiretroviral Therapy (ART), 2) Help with Primary Care Appointments, 3) Help with Issues Other than Primary Care, and 4) Where Program Visits Happen. We used LCA to assess patterns of preference, and choice simulation to estimate providers' endorsement of hypothetical CCPs. LCA identified three subgroups. The two larger subgroups (n = 133) endorsed more intensive individual program features, including directly observed therapy, home visits, and appointment reminders with accompaniment of clients to their appointments. The smallest subgroup (n = 19) endorsed medication reminders only, appointment reminders without accompaniment, and meeting at the program location rather than clients' homes. Choice simulation analysis affirmed the highest degree of endorsement (62%) for hypothetical programs combining the intensive features described above. Results indicated providers' preference for intensive program features and also reinforced the need for flexible service delivery options. Provider perspectives on service delivery approaches can inform program adjustments for successful long-term implementation, which in turn can improve patient outcomes.
{"title":"Heterogeneity of provider preferences for HIV Care Coordination Program features: latent class analysis of a discrete choice experiment.","authors":"Chunki Fong, Madellena Conte, Rebecca Zimba, Jennifer Carmona, Gina Gambone, Abigail Baim-Lance, McKaylee Robertson, Mary Irvine, Denis Nash","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The PROMISE study assessed revisions designed to facilitate implementation of an HIV care coordination program (CCP) addressing gaps in care and treatment engagement among people living with HIV in New York City (NYC). Through latent class analysis (LCA) of a discrete choice experiment (DCE), we explored heterogeneity of provider preferences regarding CCP features. From January-March 2020, 152 NYC CCP providers completed a DCE with 3-4 levels on each of 4 program attributes: 1) Help with Adherence to Antiretroviral Therapy (ART), 2) Help with Primary Care Appointments, 3) Help with Issues Other than Primary Care, and 4) Where Program Visits Happen. We used LCA to assess patterns of preference, and choice simulation to estimate providers' endorsement of hypothetical CCPs. LCA identified three subgroups. The two larger subgroups (<i>n</i> = 133) endorsed more intensive individual program features, including directly observed therapy, home visits, and appointment reminders with accompaniment of clients to their appointments. The smallest subgroup (<i>n</i> = 19) endorsed medication reminders only, appointment reminders without accompaniment, and meeting at the program location rather than clients' homes. Choice simulation analysis affirmed the highest degree of endorsement (62%) for hypothetical programs combining the intensive features described above. Results indicated providers' preference for intensive program features and also reinforced the need for flexible service delivery options. Provider perspectives on service delivery approaches can inform program adjustments for successful long-term implementation, which in turn can improve patient outcomes.</p>","PeriodicalId":13165,"journal":{"name":"HIV Research & Clinical Practice","volume":"25 1","pages":"2300923"},"PeriodicalIF":1.8,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10978435/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139512314","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-01Epub Date: 2024-10-19DOI: 10.1080/25787489.2024.2416301
{"title":"Statement of Retraction: Impact TB co-infections on immune tolerance among people living with HIV: a systematic review.","authors":"","doi":"10.1080/25787489.2024.2416301","DOIUrl":"https://doi.org/10.1080/25787489.2024.2416301","url":null,"abstract":"","PeriodicalId":13165,"journal":{"name":"HIV Research & Clinical Practice","volume":"25 1","pages":"2416301"},"PeriodicalIF":1.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142817922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Resistance to antiretrovirals against human immunodeficiency virus (HIV) poses a threat to zero transmission of HIV by 2030. Few studies have been conducted on HIV drug resistance (HIVDR) mutations targeting adolescents. We determined the prevalence, pattern of HIVDR mutations, and factors associated with unsuppressed HIV viral load among adolescents on antiretroviral therapy (ART).
Methods: From March to June 2020, we conducted a cross-sectional study at the Infectious Disease Clinic in Dar es Salaam, Tanzania. HIV-1 viral load was tested using m2000rt Real-Time HIV-1 assay. A sample with a viral load equal or more than 1,000 copies/ml was tested for HIVDR mutations. We determined the factors associated with unsuppressed viral load using logistic regression. A p-value less than 0.05 was considered significant.
Results: We enrolled 131 participants with a median age (interquartile range) of 15 (13-18) years. Of all, 24(18.3%) had a viral load above 1000 copies/ml. HIVDR mutations were found in 19/24(68.4%). Mutation to protease inhibitors, nucleotide reverse transcriptase inhibitors, and non-nucleoside reverse transcriptase inhibitors were 1(5.2%), 9(47.4%), and 11(57.9%), respectively. Non-antiretroviral therapy and orphanages were independently associated with unsuppressed viral load.
Conclusion: The prevalence of HIVDR and unsuppressed HIV viral load among adolescents are relatively high. The use of non-antiretroviral therapy and orphanage influenced the persistence of high viral load. Strategies for surveillance of HIVDR early warning signs should be devised among adolescents.
{"title":"Prevalence of human immunodeficiency virus drug resistance and factors associated with high viral load among adolescents on antiretroviral therapy in Dar Es Salaam, Tanzania.","authors":"Irene Maseke, Agricola Joachim, Doreen Kamori, Ahmed Abade, Nyambura Moremi, Mtebe Majigo","doi":"10.1080/25787489.2024.2400827","DOIUrl":"10.1080/25787489.2024.2400827","url":null,"abstract":"<p><strong>Background: </strong>Resistance to antiretrovirals against human immunodeficiency virus (HIV) poses a threat to zero transmission of HIV by 2030. Few studies have been conducted on HIV drug resistance (HIVDR) mutations targeting adolescents. We determined the prevalence, pattern of HIVDR mutations, and factors associated with unsuppressed HIV viral load among adolescents on antiretroviral therapy (ART).</p><p><strong>Methods: </strong>From March to June 2020, we conducted a cross-sectional study at the Infectious Disease Clinic in Dar es Salaam, Tanzania. HIV-1 viral load was tested using m2000rt Real-Time HIV-1 assay. A sample with a viral load equal or more than 1,000 copies/ml was tested for HIVDR mutations. We determined the factors associated with unsuppressed viral load using logistic regression. A <i>p</i>-value less than 0.05 was considered significant.</p><p><strong>Results: </strong>We enrolled 131 participants with a median age (interquartile range) of 15 (13-18) years. Of all, 24(18.3%) had a viral load above 1000 copies/ml. HIVDR mutations were found in 19/24(68.4%). Mutation to protease inhibitors, nucleotide reverse transcriptase inhibitors, and non-nucleoside reverse transcriptase inhibitors were 1(5.2%), 9(47.4%), and 11(57.9%), respectively. Non-antiretroviral therapy and orphanages were independently associated with unsuppressed viral load.</p><p><strong>Conclusion: </strong>The prevalence of HIVDR and unsuppressed HIV viral load among adolescents are relatively high. The use of non-antiretroviral therapy and orphanage influenced the persistence of high viral load. Strategies for surveillance of HIVDR early warning signs should be devised among adolescents.</p>","PeriodicalId":13165,"journal":{"name":"HIV Research & Clinical Practice","volume":"25 1","pages":"2400827"},"PeriodicalIF":1.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142153889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-01Epub Date: 2024-06-17DOI: 10.1080/25787489.2024.2361179
Angelo Brandelli Costa, Murilo Martins da Silva, Lara Wiehe Chaves, Milena Gelain, Isadora Graeff Bins-Ely, Felipe Alckmin-Carvalho, Guilherme Welter Wendt
Background: HIV-related stigma is associated with worse health outcomes and lower adherence to antiretroviral therapy. There is limited data on the stigma faced by Latin American cisgender women, although they are among the populations most affected by HIV. This study aims to provide insight into the Stigma Index Brazil, with the objective of estimating the prevalence of HIV-related stigma among cisgender women in Brazil and to investigate the role of low socioeconomic status in stigma experience.
Methods: This is a cross-sectional community-based study. A total of 30 people with HIV were trained to recruit participants from their peer networks; 1,768 people with HIV from all regions of Brazil participated in the study, of which 566 participants were cisgender women. We used the Stigma Index, an instrument that assesses global trends in HIV-related stigma from the perspective of people with HIV.
Results: Approximately 70% of participants reported some form of HIV-related stigma. The most prevalent forms were discriminatory comments or gossiping (51.26%) and verbal harassment (30.99%). More than 20% experienced any health care related HIV-stigma in the last 12 months, the most frequent being the avoidance of physical contact (10.02%). Women in social vulnerability faced more stigma compared to the group without social vulnerability, both in general contexts (75.79% vs 64.32%; χ2 = 8.67, p < 0.05) and in healthcare contexts (24.12% vs 16.02%; χ2 = 4.06, p < 0.05).
Conclusion: We found a high prevalence of stigma associated with HIV faced by Brazilian women from all regions of the country, both in everyday life and in healthcare contexts. Evidence-based interventions to reduce stigma in the general population, and specific mental health care aimed at women with HIV in Brazil, especially among those with greater socioeconomic vulnerability, are urgent.
背景:与艾滋病毒相关的污名化与较差的健康结果和较低的抗逆转录病毒治疗依从性有关。尽管拉丁美洲顺性别女性是受艾滋病毒影响最严重的人群之一,但有关她们所面临的耻辱感的数据却很有限。本研究旨在深入了解巴西的污名化指数,目的是估算巴西顺性别女性中与艾滋病相关的污名化的普遍程度,并调查低社会经济地位在污名化经历中的作用:这是一项基于社区的横断面研究。共有 30 名艾滋病病毒感染者接受了从其同伴网络中招募参与者的培训;来自巴西各地区的 1,768 名艾滋病病毒感染者参与了研究,其中 566 名参与者为顺性女性。我们使用了污名化指数,这是一种从艾滋病病毒感染者的角度评估全球艾滋病相关污名化趋势的工具:大约 70% 的参与者报告了某种形式的与 HIV 相关的污名化。最普遍的形式是歧视性评论或流言蜚语(51.26%)和言语骚扰(30.99%)。超过 20% 的人在过去 12 个月中经历过任何与医疗保健相关的艾滋病毒污名化,最常见的是避免身体接触(10.02%)。与没有社会脆弱性的群体相比,有社会脆弱性的妇女在一般情况下面临更多的污名化(75.79% vs 64.32%;χ2 = 8.67,p p 结论):我们发现,无论是在日常生活中还是在医疗保健环境中,巴西各地区的妇女都普遍面临与艾滋病毒相关的耻辱感。当务之急是采取基于证据的干预措施,减少普通人群中的污名化现象,并为巴西感染艾滋病毒的妇女,尤其是那些在社会经济方面较为脆弱的妇女提供专门的心理保健服务。
{"title":"General and healthcare-related HIV stigma among cisgender Brazilian women: the role of socioeconomic vulnerability.","authors":"Angelo Brandelli Costa, Murilo Martins da Silva, Lara Wiehe Chaves, Milena Gelain, Isadora Graeff Bins-Ely, Felipe Alckmin-Carvalho, Guilherme Welter Wendt","doi":"10.1080/25787489.2024.2361179","DOIUrl":"10.1080/25787489.2024.2361179","url":null,"abstract":"<p><strong>Background: </strong>HIV-related stigma is associated with worse health outcomes and lower adherence to antiretroviral therapy. There is limited data on the stigma faced by Latin American cisgender women, although they are among the populations most affected by HIV. This study aims to provide insight into the Stigma Index Brazil, with the objective of estimating the prevalence of HIV-related stigma among cisgender women in Brazil and to investigate the role of low socioeconomic status in stigma experience.</p><p><strong>Methods: </strong>This is a cross-sectional community-based study. A total of 30 people with HIV were trained to recruit participants from their peer networks; 1,768 people with HIV from all regions of Brazil participated in the study, of which 566 participants were cisgender women. We used the Stigma Index, an instrument that assesses global trends in HIV-related stigma from the perspective of people with HIV.</p><p><strong>Results: </strong>Approximately 70% of participants reported some form of HIV-related stigma. The most prevalent forms were discriminatory comments or gossiping (51.26%) and verbal harassment (30.99%). More than 20% experienced any health care related HIV-stigma in the last 12 months, the most frequent being the avoidance of physical contact (10.02%). Women in social vulnerability faced more stigma compared to the group without social vulnerability, both in general contexts (75.79% vs 64.32%; χ2 = 8.67, <i>p</i> < 0.05) and in healthcare contexts (24.12% vs 16.02%; χ2 = 4.06, <i>p</i> < 0.05).</p><p><strong>Conclusion: </strong>We found a high prevalence of stigma associated with HIV faced by Brazilian women from all regions of the country, both in everyday life and in healthcare contexts. Evidence-based interventions to reduce stigma in the general population, and specific mental health care aimed at women with HIV in Brazil, especially among those with greater socioeconomic vulnerability, are urgent.</p>","PeriodicalId":13165,"journal":{"name":"HIV Research & Clinical Practice","volume":"25 1","pages":"2361179"},"PeriodicalIF":1.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141330782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-01Epub Date: 2024-07-13DOI: 10.1080/25787489.2024.2356409
Sarya Swed, Hidar Alibrahim, Khaled Albakri, Mohammed Amir Rais, Safwan Al-Rassas, Wael Hafez, Bisher Sawaf, Mohammad Badr Almoshantaf, Mohamed Elsayed, Ebraheem Albazee, Huzaifa Ahmad Cheema, Wehba Hraiz, Fatima Taieb, Venus Hussain Ameen, Amine Rakab, Talha Bin Emran, Elrashed AbdElrahim, Hamid Osman, Refat Khan Pathan, Mayeen Uddin Khandaker
Background: Human immunodeficiency virus (HIV) and sexually transmitted infections (STIs) can cause severe and fatal complications; knowledge about these diseases is essential for promoting safe sex practices and modifying behaviours that are harmful to one's health. This study investigates Syrian people's understanding, attitudes, and behaviors towards HIV/AIDS and STIs, aiming to identify factors promoting safe sex practices and modifying harmful behaviors.
Methods: This online cross-sectional study was conducted in Syria between 3 September and 23 November 2022, involving all 18+ individuals. The questionnaire was adapted from a previous study containing 74 questions from five sections: socio-demographic information, knowledge and practice regarding STIs, knowledge and practice regarding HIV/AIDS, attitude towards HIV/AIDS, and attitude regarding STIs and analyzed using descriptive and multivariate logistic regression.
Results: The study involved 1073 participants mostly aged between 18-30, with 55.3% females. Over half had good awareness of STIs and HIV/AIDS, with 55% and 63% respectively. Specifically, the overall knowledge level of STI type, signs/symptoms, risks of transmission, preventive methods, and complications for untreated STIs were (45.7%), (52.9%), (58.1%), (66.1%), and (59.6%), respectively. Medical field respondents had higher knowledge of HIV (P-value < 0.05, OR = 2).
Conclusion: Our results show that Syrian people have a knowledge level of STIs and HIV was moderate. However, the attitude toward STIs was negative, as less than half of the participants had a good attitude. It is essential to solve these knowledge gaps, especially in low-income countries such as Syria.
{"title":"Evaluating knowledge, practice, and attitude of Syrian population on sexually transmitted infections and human immunodeficiency virus.","authors":"Sarya Swed, Hidar Alibrahim, Khaled Albakri, Mohammed Amir Rais, Safwan Al-Rassas, Wael Hafez, Bisher Sawaf, Mohammad Badr Almoshantaf, Mohamed Elsayed, Ebraheem Albazee, Huzaifa Ahmad Cheema, Wehba Hraiz, Fatima Taieb, Venus Hussain Ameen, Amine Rakab, Talha Bin Emran, Elrashed AbdElrahim, Hamid Osman, Refat Khan Pathan, Mayeen Uddin Khandaker","doi":"10.1080/25787489.2024.2356409","DOIUrl":"10.1080/25787489.2024.2356409","url":null,"abstract":"<p><strong>Background: </strong>Human immunodeficiency virus (HIV) and sexually transmitted infections (STIs) can cause severe and fatal complications; knowledge about these diseases is essential for promoting safe sex practices and modifying behaviours that are harmful to one's health. This study investigates Syrian people's understanding, attitudes, and behaviors towards HIV/AIDS and STIs, aiming to identify factors promoting safe sex practices and modifying harmful behaviors.</p><p><strong>Methods: </strong>This online cross-sectional study was conducted in Syria between 3 September and 23 November 2022, involving all 18+ individuals. The questionnaire was adapted from a previous study containing 74 questions from five sections: socio-demographic information, knowledge and practice regarding STIs, knowledge and practice regarding HIV/AIDS, attitude towards HIV/AIDS, and attitude regarding STIs and analyzed using descriptive and multivariate logistic regression.</p><p><strong>Results: </strong>The study involved 1073 participants mostly aged between 18-30, with 55.3% females. Over half had good awareness of STIs and HIV/AIDS, with 55% and 63% respectively. Specifically, the overall knowledge level of STI type, signs/symptoms, risks of transmission, preventive methods, and complications for untreated STIs were (45.7%), (52.9%), (58.1%), (66.1%), and (59.6%), respectively. Medical field respondents had higher knowledge of HIV (P-value < 0.05, OR = 2).</p><p><strong>Conclusion: </strong>Our results show that Syrian people have a knowledge level of STIs and HIV was moderate. However, the attitude toward STIs was negative, as less than half of the participants had a good attitude. It is essential to solve these knowledge gaps, especially in low-income countries such as Syria.</p>","PeriodicalId":13165,"journal":{"name":"HIV Research & Clinical Practice","volume":"25 1","pages":"2356409"},"PeriodicalIF":1.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141603570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Arianna E Kousari, Melissa P Wilson, Kellie L Hawkins, Mohamed Mehdi Bandali, Andrés F Henao-Martínez, Edward M Gardner, Kristine M Erlandson
Background: Weight gain has been well-described with integrase strand transfer inhibitors (INSTIs) and tenofovir alafenamide (TAF). Doravirine (DOR) has been identified as a relatively "weight-neutral" drug; however, there is little data describing its effect on weight change in routine clinical practice.
Methods: We conducted a retrospective chart review of weight change among people with HIV changing from an INSTI- to a non-INSTI regimen with DOR.
Results: At the time of ART switch, among 49 people with HIV, the mean age was 47 years, 24% were female, and 75% had HIV-1 viral load <200 copies/mL. Most (55%) people with HIV were taking bictegravir/TAF/emtricitabine prior to the switch. Although 84% switched due to concerns about weight gain, only 16% had a weight gain of ≥10% in the year preceding, and 49% had no substantial change in weight. 86% switched to DOR/lamivudine/tenofovir disoproxil fumarate. A weight decrease (-2.6% [95% CI: -5.1, -0.1%, p = .041] was seen over the year following the ART switch. Weight change prior to switch was greatest in the year 2021 compared to 2019, 2020, and 2022.
Conclusions: Overall, modest changes in weight were seen following ART switch from INSTI-based regimen to a DOR-based, non-INSTI regimen. Further investigations with larger people with HIV cohorts will be helpful to guide clinical practice, while the impact of the COVID-19 pandemic on weight change should also be considered.
背景:关于整合酶链转移抑制剂(INSTIs)和替诺福韦阿拉非酰胺(TAF)体重增加的描述很多。多拉韦林(DOR)被认为是一种相对 "不影响体重 "的药物;然而,在常规临床实践中,几乎没有数据说明其对体重变化的影响:我们对从 INSTI 方案转为使用 DOR 的非 INSTI 方案的 HIV 感染者的体重变化进行了回顾性病历审查:在转换抗逆转录病毒疗法时,49 名 HIV 感染者的平均年龄为 47 岁,24% 为女性,75% 的 HIV-1 病毒载量在转换抗逆转录病毒疗法后的一年中有所下降。与 2019 年、2020 年和 2022 年相比,2021 年转换前的体重变化最大:总体而言,从以 INSTI 为基础的抗逆转录病毒疗法转为以 DOR 为基础的非 INSTI疗法后,体重变化不大。对更大规模的艾滋病毒感染者队列进行进一步调查将有助于指导临床实践,同时还应考虑 COVID-19 大流行对体重变化的影响。
{"title":"Weight change with antiretroviral switch from integrase inhibitor or tenofovir alafenamide-based to Doravirine-Based regimens in people with HIV.","authors":"Arianna E Kousari, Melissa P Wilson, Kellie L Hawkins, Mohamed Mehdi Bandali, Andrés F Henao-Martínez, Edward M Gardner, Kristine M Erlandson","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Weight gain has been well-described with integrase strand transfer inhibitors (INSTIs) and tenofovir alafenamide (TAF). Doravirine (DOR) has been identified as a relatively \"weight-neutral\" drug; however, there is little data describing its effect on weight change in routine clinical practice.</p><p><strong>Methods: </strong>We conducted a retrospective chart review of weight change among people with HIV changing from an INSTI- to a non-INSTI regimen with DOR.</p><p><strong>Results: </strong>At the time of ART switch, among 49 people with HIV, the mean age was 47 years, 24% were female, and 75% had HIV-1 viral load <200 copies/mL. Most (55%) people with HIV were taking bictegravir/TAF/emtricitabine prior to the switch. Although 84% switched due to concerns about weight gain, only 16% had a weight gain of ≥10% in the year preceding, and 49% had no substantial change in weight. 86% switched to DOR/lamivudine/tenofovir disoproxil fumarate. A weight decrease (-2.6% [95% CI: -5.1, -0.1%, <i>p</i> = .041] was seen over the year following the ART switch. Weight change prior to switch was greatest in the year 2021 compared to 2019, 2020, and 2022.</p><p><strong>Conclusions: </strong>Overall, modest changes in weight were seen following ART switch from INSTI-based regimen to a DOR-based, non-INSTI regimen. Further investigations with larger people with HIV cohorts will be helpful to guide clinical practice, while the impact of the COVID-19 pandemic on weight change should also be considered.</p>","PeriodicalId":13165,"journal":{"name":"HIV Research & Clinical Practice","volume":"25 1","pages":"2339576"},"PeriodicalIF":1.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12008775/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141237812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-01Epub Date: 2024-09-05DOI: 10.1080/25787489.2024.2398869
Anzibert Andrew Rugakingira, Emili Yondu, Joseph Matobo Thobias, Ikunda Dionis, Costantine Chasama Kamata, Manase Kilonzi, Emmy Metta, Nathanael Sirili
Background: People living with HIV and non-communicable diseases (NCDs) are reported to experience challenges in accessing affordable and high-quality NCD care services. Consequently, the World Health Organization (WHO) recommends care integration of NCDs within the HIV services in resource-limited regions. The available opportunities and challenges need to be understood and addressed for an effective integration process. This study explored opportunities and challenges for integrating NCDs within HIV care and treatment services in Tanzania.
Methods: An exploratory qualitative case study was conducted in Tanzania between April and July 2022. A total of 22 key informants working at the ministerial level, supervising the provision of healthcare services in Tanzania, were recruited purposefully for in-depth interviews. Thematic analysis was employed during the study.
Results: Several opportunities were identified in the study for HIV/NCD services integration including the existence of an integration policy, the availability of regulations and guidelines, the existence of donor support, the presence of physical space and reliable information and communication systems, human resources adequacy, and political will to support the process. However, participants voiced concerns over the costs related to service integration, difficulties in reallocating donor funds, and hesitance of the healthcare providers as likely challenges to effective integration.
Conclusion: The findings of this study underscore that the effective and sustainable care integration of NCDs within HIV services relies on the availability of policy, funds, infrastructures, human resources, and stakeholders' willingness to support the process.
{"title":"Opportunities and challenges for the integration of managing non-communicable diseases within HIV care and treatment services in Tanzania.","authors":"Anzibert Andrew Rugakingira, Emili Yondu, Joseph Matobo Thobias, Ikunda Dionis, Costantine Chasama Kamata, Manase Kilonzi, Emmy Metta, Nathanael Sirili","doi":"10.1080/25787489.2024.2398869","DOIUrl":"10.1080/25787489.2024.2398869","url":null,"abstract":"<p><strong>Background: </strong>People living with HIV and non-communicable diseases (NCDs) are reported to experience challenges in accessing affordable and high-quality NCD care services. Consequently, the World Health Organization (WHO) recommends care integration of NCDs within the HIV services in resource-limited regions. The available opportunities and challenges need to be understood and addressed for an effective integration process. This study explored opportunities and challenges for integrating NCDs within HIV care and treatment services in Tanzania.</p><p><strong>Methods: </strong>An exploratory qualitative case study was conducted in Tanzania between April and July 2022. A total of 22 key informants working at the ministerial level, supervising the provision of healthcare services in Tanzania, were recruited purposefully for in-depth interviews. Thematic analysis was employed during the study.</p><p><strong>Results: </strong>Several opportunities were identified in the study for HIV/NCD services integration including the existence of an integration policy, the availability of regulations and guidelines, the existence of donor support, the presence of physical space and reliable information and communication systems, human resources adequacy, and political will to support the process. However, participants voiced concerns over the costs related to service integration, difficulties in reallocating donor funds, and hesitance of the healthcare providers as likely challenges to effective integration.</p><p><strong>Conclusion: </strong>The findings of this study underscore that the effective and sustainable care integration of NCDs within HIV services relies on the availability of policy, funds, infrastructures, human resources, and stakeholders' willingness to support the process.</p>","PeriodicalId":13165,"journal":{"name":"HIV Research & Clinical Practice","volume":"25 1","pages":"2398869"},"PeriodicalIF":1.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142132591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-01Epub Date: 2024-06-21DOI: 10.1080/25787489.2024.2363129
Sofia B Fernandez, Rahel Dawit, Ekpereka Sandra Nawfal, Melissa K Ward, Daisy Ramírez-Ortiz, Diana M Sheehan, Mary Jo Trepka
Background: COVID-19 profoundly and uniquely impacted people with HIV. People with HIV experienced significant psychosocial and socioeconomic impacts, yet a limited amount of research has explored potential differences across gender and racial/ethnic groups of people with HIV.
Objective: The objective of this study was to examine psychosocial and socioeconomic stressors related to the COVID-19 pandemic among a diverse sample of people with HIV in South Florida and to determine if the types of stressors varied across gender and racial/ethnic groups.
Methods: We analyzed data from a cross-sectional survey with Miami-Dade County, Ryan White Program recipients. Outcomes included mental health, socioeconomic, drug/alcohol, and care responsibility/social support changes. Weighted descriptive analyses provided an overview of stressors by gender and racial/ethnic group and logistic regressions estimated associations between demographics and stressors.
Results: Among 291 participants, 39% were Non-Hispanic Black, 18% were Haitian, and 43% were Hispanic. Adjusting for age, sex, language, and foreign-born status, Hispanics were more likely to report several worsened mental health (i.e. increased loneliness, anxiety) and socioeconomic stressors (i.e. decreased income). Spanish speakers were more likely to report not getting the social support they needed. Women were more likely to report spending more time caring for children.
Conclusions: Findings highlight ways in which cultural and gender expectations impacted experiences across people with HIV and suggest strategies to inform interventions and resources during lingering and future public health emergencies. Results suggest that public health emergencies have different impacts on different communities. Without acknowledging and responding to differences, we risk losing strides towards progress in health equity.
背景:COVID-19 对 HIV 感染者产生了深刻而独特的影响。艾滋病病毒感染者经历了重大的社会心理和社会经济影响,但探讨不同性别和种族/民族艾滋病病毒感染者之间潜在差异的研究数量有限:本研究旨在调查南佛罗里达州不同样本的 HIV 感染者中与 COVID-19 大流行相关的社会心理和社会经济压力,并确定不同性别和种族/民族群体的压力类型是否存在差异:我们对迈阿密-戴德县瑞安-怀特计划受助者的横截面调查数据进行了分析。结果包括心理健康、社会经济、毒品/酒精和护理责任/社会支持的变化。加权描述性分析提供了按性别和种族/民族群体划分的压力因素概览,逻辑回归估算了人口统计学和压力因素之间的关联:在 291 名参与者中,39% 为非西班牙裔黑人,18% 为海地人,43% 为西班牙裔。在对年龄、性别、语言和外国出生身份进行调整后,西班牙裔更有可能报告心理健康恶化(即孤独感和焦虑感增加)和社会经济压力(即收入减少)。讲西班牙语的人更有可能报告说他们得不到所需的社会支持。妇女更有可能表示花了更多的时间照顾子女:研究结果凸显了文化和性别期望对艾滋病毒感染者的经历产生影响的方式,并提出了在持续的和未来的公共卫生突发事件中为干预措施和资源提供信息的策略。研究结果表明,突发公共卫生事件对不同社区的影响各不相同。如果不承认和应对这些差异,我们就有可能在实现健康公平方面失去进展。
{"title":"Psychosocial and socioeconomic changes among low-income people with HIV during the COVID-19 pandemic in Miami-Dade County, Florida: racial/ethnic and gender differences.","authors":"Sofia B Fernandez, Rahel Dawit, Ekpereka Sandra Nawfal, Melissa K Ward, Daisy Ramírez-Ortiz, Diana M Sheehan, Mary Jo Trepka","doi":"10.1080/25787489.2024.2363129","DOIUrl":"10.1080/25787489.2024.2363129","url":null,"abstract":"<p><strong>Background: </strong>COVID-19 profoundly and uniquely impacted people with HIV. People with HIV experienced significant psychosocial and socioeconomic impacts, yet a limited amount of research has explored potential differences across gender and racial/ethnic groups of people with HIV.</p><p><strong>Objective: </strong>The objective of this study was to examine psychosocial and socioeconomic stressors related to the COVID-19 pandemic among a diverse sample of people with HIV in South Florida and to determine if the types of stressors varied across gender and racial/ethnic groups.</p><p><strong>Methods: </strong>We analyzed data from a cross-sectional survey with Miami-Dade County, Ryan White Program recipients. Outcomes included mental health, socioeconomic, drug/alcohol, and care responsibility/social support changes. Weighted descriptive analyses provided an overview of stressors by gender and racial/ethnic group and logistic regressions estimated associations between demographics and stressors.</p><p><strong>Results: </strong>Among 291 participants, 39% were Non-Hispanic Black, 18% were Haitian, and 43% were Hispanic. Adjusting for age, sex, language, and foreign-born status, Hispanics were more likely to report several worsened mental health (i.e. increased loneliness, anxiety) and socioeconomic stressors (i.e. decreased income). Spanish speakers were more likely to report not getting the social support they needed. Women were more likely to report spending more time caring for children.</p><p><strong>Conclusions: </strong>Findings highlight ways in which cultural and gender expectations impacted experiences across people with HIV and suggest strategies to inform interventions and resources during lingering and future public health emergencies. Results suggest that public health emergencies have different impacts on different communities. Without acknowledging and responding to differences, we risk losing strides towards progress in health equity.</p>","PeriodicalId":13165,"journal":{"name":"HIV Research & Clinical Practice","volume":"25 1","pages":"2363129"},"PeriodicalIF":1.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11256985/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141440431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}